![Leiden Dworak](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermögen: - $ am 31.05.2026
Leiden Dworak worked as Director at Moderna, Inc., VP, Head-Finance Planning & Analysis at AVROBIO, Inc., and Chief Accounting Officer at TScan Therapeutics, Inc. from 2025 to 2026.
Education includes an MBA from Indiana University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 20.01.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
| TSCAN THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 10.04.2026 |
| MODERNA, INC. | Direktor/Vorstandsmitglied | - |
| TECTONIC THERAPEUTIC, INC. | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 4 |
|---|---|
Indiana University
 Indiana University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AVROBIO, Inc.
 AVROBIO, Inc. BiotechnologyHealth Technology Develops potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases in a single dose | Health Technology |
TScan Therapeutics, Inc.
 TScan Therapeutics, Inc. BiotechnologyHealth Technology Develops T-cell therapies for cancer patients | Health Technology |
Moderna, Inc.
 Moderna, Inc. BiotechnologyHealth Technology Researches, develops, manufactures and commercializes mRNA-based respiratory & other virus vaccines, oncology and rare disease therapeutics | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
